Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,639.35
(
-1.14%
)
US TECH 100
23,908.00
(
-0.93%
)
Dow Jones
46,279.15
(
-1.52%
)
Brent Oil
105.72
(
5.03%
)
Bitcoin
71,251.30
(
-3.64%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 104590

Sunday, 09/19/2010 8:50:30 PM

Sunday, September 19, 2010 8:50:30 PM

Post# of 257253

…isn't the AF trial just another step for the broader indication?

Not really—stroke prevention secondary to AF is an indication with its own unique characteristics. Success by the new oral anticoagulants in AF/stroke prevention is not strongly prognostic of success in VTE treatment (the most important inpatient indication for Lovenox), VTE prevention (the most important outpatient indication for Lovenox), or ACS (the indication addressed by M118).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now